Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Participate in Upcoming Conferences

DUBLIN, Ireland, May 26, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
May 25, 2017 13:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Named One of the Best Workplaces in Chicago by Fortune

DUBLIN, Ireland, May 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
May 23, 2017 16:05 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.

DUBLIN, Ireland, May 23, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
May 15, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topical solution) 2% w/w Patent

DUBLIN, Ireland, May 15, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
May 11, 2017 09:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association Luminary

DUBLIN, Ireland, May 11, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
May 08, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance

-- First-Quarter 2017 Net Sales of $220.9 Million; Up 8 Percent -- -- First-Quarter 2017 Net Loss of $90.6 Million; Adjusted EBITDA of $51.9 Million -- -- First-Quarter 2017 Net Sales from Rare...
May 08, 2017 06:55 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease

- Pivotal Trial of Teprotumumab in Thyroid Eye Disease (TED) Expected to Begin in Second Half of 2017 - - Teprotumumab Phase 2...
May 01, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older

DUBLIN, Ireland, May 01, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
April 13, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on May 8, 2017

DUBLIN, Ireland, April 13, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
April 12, 2017 11:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Named One of the Best Workplaces in Health Care by Great Place to Work® and Fortune Magazine

DUBLIN, Ireland, April 12, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...